---
title: "Hisoar Pharmaceutical's Diquafosol Sodium Gets Nod to Enter South Korean Market"
date: "2025-02-07 15:45:09"
summary: "Zhejiang Hisoar Pharmaceutical's raw drug material, diquafosol sodium, obtained an active pharmaceutical ingredient or API drug registration certificate from South Korea's Ministry of Food and Drug Safety, according to a Shenzhen Stock Exchange filing on Friday. The Chinese pharmaceutical company will be authorized to market diquafosol sodium in the South..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Zhejiang Hisoar Pharmaceutical's raw drug material, diquafosol sodium, obtained an active pharmaceutical ingredient or API drug registration certificate from South Korea's Ministry of Food and Drug Safety, according to a Shenzhen Stock Exchange filing on Friday.

The Chinese pharmaceutical company will be authorized to market diquafosol sodium in the South Korean market. The product's eye drop formulation is used to treat dry eye, the filing said.

The company's shares closed less than 3% higher.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250207:G2464983:0/)
